Clinical trial · Observational
Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma
A Retrospective Study
NCT04873180CI-TRIAL-00051673completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sectioning and staining of renal neoplasms after nephrectomy operation | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- expression of survivin in neoplastic and adjacent normal renal tissues
- timeFrame
- april, 2021
- description
- Survivin is highly expressed in neoplastic renal tissues compared to normal ones by immunohistochemical measures..
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patients suffer from renal cell carcinomas Exclusion Criteria: * patients received pre-operative chemotherapy or radiotherapy. patients with insufficient clinical data.
References
Publications (0)
Data not yet available
No reference posted for this study.